Advanced in HER2 Negative Breast Cancer

Meritxell Bellet

Barcelona, CT, ES 
Advanced in HER2 Negative Breast Cancer
Barcelona, CT, ES 
OverviewLocationsClinical Research

Overview

Meritxell Bellet practices in Barcelona, Spain. Ms. Bellet is rated as an Advanced expert by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Menopause, Triple-Negative Breast Cancer, and HER2 Negative Breast Cancer.

Her clinical research consists of co-authoring 49 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Barcelona, CT, Spain
Other Locations
Spain
Bellaterra, CT, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

An Open-Label, Randomized Phase 2 Study of the Impact of Food on Tolerability When Receiving Abemaciclib for Patients With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
An Open-Label, Randomized Phase 2 Study of the Impact of Food on Tolerability When Receiving Abemaciclib for Patients With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: April 02, 2024
Intervention Type: Drug
Study Drug: Abemaciclib
Study Phase: Phase 2
International,Multicenter,Randomized,Open-label, Phase II to Evaluate the Efficacy and Safety of Continuation of Palbociclib+2nd Line Endocrine Therapy in HR+/HER2- ABC Patients Who Had Clinical Benefit During 1st Line Palbociclib.
International,Multicenter,Randomized,Open-label, Phase II to Evaluate the Efficacy and Safety of Continuation of Palbociclib+2nd Line Endocrine Therapy in HR+/HER2- ABC Patients Who Had Clinical Benefit During 1st Line Palbociclib.
Enrollment Status: Completed
Publish Date: September 07, 2023
Intervention Type: Drug
Study Drugs: Palbociclib, Endocrine Therapy
Study Phase: Phase 2
Elacestrant in Preoperative Setting, a Window of Opportunity Study
Elacestrant in Preoperative Setting, a Window of Opportunity Study
Enrollment Status: Completed
Publish Date: October 26, 2022
Intervention Type: Drug
Study Drug: Elacestrant
Study Phase: Early Phase 1
A Window of Opportunity Trial of Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor-Positive and HER2-negative Breast Cancer
A Window of Opportunity Trial of Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor-Positive and HER2-negative Breast Cancer
Enrollment Status: Completed
Publish Date: April 01, 2022
Intervention Type: Drug
Study Drug: Onapristone
Study Phase: Early Phase 1
Neoadjuvant Letrozole + Palbociclib in Patients With II-IIIB BC,HR+, HER2-, Phenotype and Pretreatment Recurrence Score(RS):18-25 or 26-100 by Oncotype DX Breast RS Assay.Analysis of RS and Pathological Changes at Surgery
Neoadjuvant Letrozole + Palbociclib in Patients With II-IIIB BC,HR+, HER2-, Phenotype and Pretreatment Recurrence Score(RS):18-25 or 26-100 by Oncotype DX Breast RS Assay.Analysis of RS and Pathological Changes at Surgery
Enrollment Status: Completed
Publish Date: November 27, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

49 Total Publications

Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis.
Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis.
Journal: Cancer treatment reviews
Published: October 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Bellet's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile